<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106613</url>
  </required_header>
  <id_info>
    <org_study_id>FJ-228-0001</org_study_id>
    <nct_id>NCT00106613</nct_id>
    <nct_alias>NCT00058630</nct_alias>
    <nct_alias>NCT00060216</nct_alias>
  </id_info>
  <brief_title>A Research Study for Patients With Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell
      carcinoma (RCC) patients who have developed progressive disease (PD) following or during
      treatment with immunotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2003</start_date>
  <completion_date type="Actual">August 1, 2004</completion_date>
  <primary_completion_date type="Actual">August 1, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the rate of objective response (the best response of Complete Response (CR), Partial Response (PR)).</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of disease control, Complete Response, Partial Response, or Stable Disease</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to objective disease progression.</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from screening assessment to the final study visit in Karnofsky performance status.</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state plasma concentrations</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>FK228 (romidepsin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13 mg/m2 of romidepsin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK228 (romidepsin)</intervention_name>
    <description>Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.</description>
    <arm_group_label>FK228 (romidepsin)</arm_group_label>
    <other_name>romidepsin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must fulfill all of the following criteria to be eligible for study participation:

          -  Age ≥ 18 years;

          -  Histologically confirmed Renal Cell Carcinoma (RCC);

          -  Metastatic disease, with measurable lesions according to the Response Evaluation
             Criteria in Solid Tumors (RECIST);

          -  Failure of prior cytokine therapy;

          -  Documented progressive disease;

        Exclusion Criteria:

        Patients are ineligible for entry if any of the following criteria are met:

          -  Significant cardiac disease including congestive heart failure, history of myocardial
             infarction within one year, uncontrolled dysrhythmias, or poorly controlled angina

          -  History of serious ventricular arrhythmia

          -  Corrected QT interval (QTc) ≥ 500 msec

          -  Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C;

          -  Previous extensive radiotherapy involving ≥ 30% of bone marrow

          -  Coexistent second malignancy or history of prior malignancy within previous 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William McCulloch, MB, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Gloucester Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.</citation>
    <PMID>29936064</PMID>
  </reference>
  <reference>
    <citation>Wolchok J. Putting the Immunologic Brakes on Cancer. Cell. 2018 Nov 29;175(6):1452-1454. doi: 10.1016/j.cell.2018.11.006. Review.</citation>
    <PMID>30500529</PMID>
  </reference>
  <reference>
    <citation>Mansfield AS, Jen J. Predicting Treatment Response Based on RNA Expression in Large Datasets. Clin Cancer Res. 2019 Mar 1;25(5):1443-1445. doi: 10.1158/1078-0432.CCR-18-2823. Epub 2018 Nov 16.</citation>
    <PMID>30446588</PMID>
  </reference>
  <reference>
    <citation>Pal SK, Forero-Torres A, Thompson JA, Morris JC, Chhabra S, Hoimes CJ, Vogelzang NJ, Boyd T, Bergerot PG, Adashek JJ, Li H, Yu X, Gartner EM, Carret AS, Smith DC. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. Cancer. 2019 Apr 1;125(7):1124-1132. doi: 10.1002/cncr.31912. Epub 2019 Jan 9.</citation>
    <PMID>30624766</PMID>
  </reference>
  <reference>
    <citation>Stadler W, et al. A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4669.</citation>
  </reference>
  <results_reference>
    <citation>Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006 Jun;5(1):57-60.</citation>
    <PMID>16859580</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 28, 2005</study_first_submitted>
  <study_first_submitted_qc>March 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2005</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Metastatic Renal Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

